恒瑞医药(600276)：每股净资产 5.23元，每股净利润 1.1元，历史净利润年均增长 30.79%，预估未来三年净利润年均增长 28.72%，更多数据见：恒瑞医药600276核心经营数据 恒瑞医药的当前股价 80.59元，市盈率 72.91，未来三年的估值假设和预期收益率如下：15倍PE，预期收益率 -63.61%；20倍PE，预期收益率 -51.48%；25倍PE，预期收益率 -39.35%；30倍PE，预期收益率 -27.22%。 华东医药(000963)：每股净资产 6.66元，每股净利润 1.55元，历史净利润年均增长 37.67%，预估未来三年净利润年均增长 21.0%，更多数据见：华东医药000963核心经营数据 华东医药的当前股价 17.89元，市盈率 11.72，未来三年的估值假设和预期收益率如下：15倍PE，预期收益率 91.86%；20倍PE，预期收益率 155.82%；25倍PE，预期收益率 219.77%；30倍PE，预期收益率 283.72%。 一、vTvTherapeutics公司公布的部分二期数据【2017年9月披露】 vTvTherapeutics公司于2017年在美国完成Ⅱ期临床研究，该试验针对二甲双胍固定剂量治疗的T2D患者（N=174），安慰剂对照以评价TTP-273连续口服3个月（150mg；每日午后一次qpm、或者每日两次bid）的血糖控制（HbA1c变化，主要终点）和体重变化（次要终点）。2017年9月，在葡萄牙举行的第53届EASD年会上，该公司宣布Ⅱ期临床达到预期目标（HbA1c和体重变化），如下图。安全性方面，药物耐受性良好，TTP-273治疗臂未出现相同作用机制的多肽类药物常见的呕吐不良事件，恶心发生率也比安慰剂组低（7.3%vs 3.4% qpm vs5.0%bid）。该药qpm剂量比bid剂量似乎效果更优，该公司原本也计划在中国评估较低剂量的安全性和有效性。 HbA1c和体重变化 另外还提出了基于体重和较低剂量的子集数据，对于体重≥100kg的人群，给予低剂量（150mgqpm）的患者3月时相对基线的HbA1c降低值比安慰剂患者低1.4%，体重降低的数值比安慰剂患者低2.47kg（如下图），与已上市的利拉鲁肽、利西拉肽、艾塞那肽缓释制剂相似。 基于体重和较低剂量的子集数据 点评：TTP273对于不是很肥胖的人群HbA2C和体重效果不太理想，当然这一部分试验数据，不能说明问题。 二、C&EN期刊对于vTvTherapeutics公司的一篇报道 Scientists at vTv tell C&EN that the stakes are high in developing a GLP-1 drug. “Thisis a very competitive area,” says Robert Andrews, a medicinal chemist who ledthe team that discovered vTv’s lead molecule, TTP273. Andrews describes the company’s technology as a combination of computational work and real-life testing of candidates in animals and cell lines, what he calls “fast,parallel chemistry.” Using a library of 60,000 probes, the team at vTv first set out to find what might bind to any part of the GLP-1 receptor on the surface of cells. At the same time, the researchers were docking all 60,000 of these probes in their modeling system, looking for hits that could have some biological readout. The likely candidates are where there are similarities between their computer experiments and their cell experiments, Andrews says. These candidates become the building blocks for molecules like TTP273 and its predecessor, TTP054. Developing the compounds was full of bumps, he says. “We hit at least four, maybe five progression cliffs where we worked for a while toget agonist activity increases, and suddenly we found it, and then worked toimprove first-pass metabolism, and got that,” he says. “You might work for amonth or two and not see any progress, and then one compound changeseverything.” In a Phase II study completed in 2017, TTP273 appeared safe, but it didn’t lower A1c levels and prompt weight loss as well as vTv had hoped. The company has partnered with Hangzhou Zhongmei Huadong Pharmaceutical to further develop the molecule. 来源网址：An oral form of a blockbuster diabetes drug has arrived. Will people be able to get it? (acs.org) 点评：总体这篇的报道结论和上面的试验数据差不多。数据没有达到期望（but it didn’t lower A1c levels and prompt weight loss as well as vTv had hoped.) 三、相信华东能够解决技术问题 预计二期1年半左右，明年半年二期会结束，明年底能顺利开展三期，就问题不大了。 #华东医药# $华东医药(SZ000963)$ $恒瑞医药(SH600276)$ $信立泰(SZ002294)$ 作者：牛顿惯性定律原文链接：https://xueqiu.com/7198180813/170425677 转载请注明：www.51xianjinliu.com » 华东医药TTP273美国Ⅱ期临床数据 喜欢 (0)or分享 (0)
